Replies to post #3679 on Ligand Pharmaceuticals Inc (LGND)

[S-BEES-BUMBLEBEE]

$LGND >>> Annual report: https://ih.advfn.com/stock-market/NASDAQ/ligand-pharmaceuticals-LGND/stock-news/87415231/annual-report-10-k

E.g. out of latest annual report: "TR-Beta - VK2809 and VK0214 (Viking)
Our partner, Viking, is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia and NASH. VK2809 is currently in a Phase 2b clinical trial (the VOYAGE study) in patients with biopsy-confirmed NASH. Viking has previously announced positive results from a Phase 2a trial of VK2809 in hypercholesterolemia and fatty liver disease. VK0214 is currently in Phase 1 clinical development, and had been granted orphan drug study by the FDA for the treatment of X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales. Our TR Beta programs partnered with Viking are subject to CVR sharing and a portion of the cash received will be paid out to CVR holders."

$LGNZZ $LGNYZ $LGNXZ $LGNDZ >>> Get ready folks, dividend payments to CVR holders imminent soon per my DD. *NFA ~ DYOR, please! GLTYA.

$LGNXZ is Glucagon
$LGNDZ is Roche
$LGNZZ is Beta
$LGNYZ is General



$$$LGND$$$ $$$LGNYZ$$$ $$$LGNXZ$$$ $$$LGNDZ$$$ $$$LGNZZ$$$